Advisory Board endorses Clinical Ph 2b strategy
Rejuvenate Biomed organized a Clinical Advisory Board meeting to discuss the clinical development of lead candidate RJx-01 in sarcopenia.
Groundbreaking clinical trial started
The first clinical trial with RJx-01 has started in disuse-induced muscle atrophy, marking Rejuvenate Biomed’s maturation to a clinical-stage company.
€15.7 million Series B round secured
This round was led by Rejuveron Life Sciences and Vesalius Biocapital. The funding is being used to accelerate the clinical development of RJx-01.
Preclinical data reviewed by Scientific Advisory Board
The SAB concluded that the preclinical data of RJx-01 demonstrate proof-of-principle for sarcopenia, and show potential in multiple other muscle- and non-muscle-related disorders.
Committed to a sustainable future
After identifying 5 core Sustainable Development Goals, Rejuvenate Biomed defined company actions to reach these goals for a sustainable future.